Literature DB >> 2253778

Involvement of thymosin beta 4 and endoproteinase Asp-N in the biosynthesis of the tetrapeptide AcSerAspLysPro a regulator of the hematopoietic system.

C Grillon1, K Rieger, J Bakala, D Schott, J L Morgat, E Hannappel, W Voelter, M Lenfant.   

Abstract

It is shown that AcSDKP a new regulator of the hematopoietic system can be generated from thymosin beta 4 by a one-step enzymatic cleavage in vitro and in vivo. AcSDKP and T beta 4 were both detected in bone marrow cells (BMC). Incubation of [3H]T beta 4 with either intact or lysed BMC led to the formation of [3H]AcSDKP whereas the labelled tetrapeptide was not degraded under these conditions. Model enzymatic degradation of T beta 4 carried out with bacterial enzymes suggests that a mammalian endoproteinase Asp-N might be involved in the formation of AcSDKP through the specific cleavage of the 4Pro-5 Asp peptide bond of T beta 4.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2253778     DOI: 10.1016/0014-5793(90)81322-f

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  22 in total

1.  Influence of cyclic AMP and serum factors upon expression of a retinoid-responsive gene in neuroblastoma cells.

Authors:  A K Hall
Journal:  J Mol Neurosci       Date:  1992       Impact factor: 3.444

2.  Expression of thymosin beta-4 and related genes in developing human brain.

Authors:  M R Condon; A K Hall
Journal:  J Mol Neurosci       Date:  1992       Impact factor: 3.444

3.  The complete sequences of trout (Salmo gairdneri) thymosin beta 11 and its homologue thymosin beta 12.

Authors:  P P Yialouris; B Coles; O Tsitsiloni; B Schmid; S Howell; A Aitken; W Voelter; A A Haritos
Journal:  Biochem J       Date:  1992-04-15       Impact factor: 3.857

4.  Distribution and biological activity ofβ-thymosins.

Authors:  M Mihelić; W Voelter
Journal:  Amino Acids       Date:  1994-02       Impact factor: 3.520

5.  AcSDKP: a new potential marker of malignancy of the thyroid gland.

Authors:  Michal Kusinski; Joanna Wdzieczak-Bakala; Jian-Miao Liu; Jerome Bignon; Krzysztof Kuzdak
Journal:  Langenbecks Arch Surg       Date:  2006-01-18       Impact factor: 3.445

6.  Treatment of traumatic brain injury in rats with N-acetyl-seryl-aspartyl-lysyl-proline.

Authors:  Yanlu Zhang; Zheng Gang Zhang; Michael Chopp; Yuling Meng; Li Zhang; Asim Mahmood; Ye Xiong
Journal:  J Neurosurg       Date:  2016-05-20       Impact factor: 5.115

7.  Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts.

Authors:  N E Rhaleb; H Peng; P Harding; M Tayeh; M C LaPointe; O A Carretero
Journal:  Hypertension       Date:  2001-03       Impact factor: 10.190

Review 8.  The biological significance of angiotensin-converting enzyme inhibition to combat kidney fibrosis.

Authors:  Takako Nagai; Kyoko Nitta; Megumi Kanasaki; Daisuke Koya; Keizo Kanasaki
Journal:  Clin Exp Nephrol       Date:  2014-07-01       Impact factor: 2.801

9.  N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo.

Authors:  Dahai Wang; Oscar A Carretero; Xiao-Yi Yang; Nour-Eddine Rhaleb; Yun-He Liu; Tang-Dong Liao; Xiao-Ping Yang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-07-15       Impact factor: 4.733

10.  Combination treatment with N-acetyl-seryl-aspartyl-lysyl-proline and tissue plasminogen activator provides potent neuroprotection in rats after stroke.

Authors:  Li Zhang; Michael Chopp; Hua Teng; Guangliang Ding; Quan Jiang; Xiao Ping Yang; Nour Eddine Rhaleb; Zheng Gang Zhang
Journal:  Stroke       Date:  2014-02-18       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.